Where Pear Therapeutics Stands With Analysts
Within the last quarter, Pear Therapeutics (NASDAQ:PEAR) has observed the following analyst ratings:
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Pear rapeutics
Pear Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Pear Therapeutics's (NASDAQ:PEAR) reported sales totaled $2.75 million. Despite a 62.5% increase in earnings, the company posted a loss of $23.86 million.
Benzinga ·
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Places
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
